Posted on May 23, 2022
Pfizer says its COVID-19 vaccine produces a strong immune response in kids under 5
407
11
2
8
8
0
https://www.npr.org/2022/05/23/ [login to see] /pfizer-covid-vaccine-under-5
A third pediatric dose of the Pfizer-BioNTech COVID-19 vaccine in children 6 months to under 5 years of age prompted a strong immune response, with a safety profile that was similar to placebo, the companies said.
Pfizer's pediatric COVID-19 vaccine has an efficacy of 80.3%, according to a preliminary analysis, and meets "all immunobridging criteria required for Emergency Use Authorization," the company said Monday. The results are based on clinical trials in which kids from six months to age 5 got three doses of the company's vaccine.
Pfizer and its partner, BioNTech, plan to submit the new data to the Food and Drug Administration this week, bringing families with young children one step closer to a long-awaited vaccine.
The size of Pfizer's pediatric dose is one-tenth of its adult dose. The company had originally tested a two-dose regimen, but mixed results prompted Pfizer to test a three-dose regimen.
The third dose was "well tolerated among 1,678 children under 5 years of age with a safety profile similar to placebo," Pfzier said as it announced the news.
A third pediatric dose of the Pfizer-BioNTech COVID-19 vaccine in children 6 months to under 5 years of age prompted a strong immune response, with a safety profile that was similar to placebo, the companies said.
Pfizer's pediatric COVID-19 vaccine has an efficacy of 80.3%, according to a preliminary analysis, and meets "all immunobridging criteria required for Emergency Use Authorization," the company said Monday. The results are based on clinical trials in which kids from six months to age 5 got three doses of the company's vaccine.
Pfizer and its partner, BioNTech, plan to submit the new data to the Food and Drug Administration this week, bringing families with young children one step closer to a long-awaited vaccine.
The size of Pfizer's pediatric dose is one-tenth of its adult dose. The company had originally tested a two-dose regimen, but mixed results prompted Pfizer to test a three-dose regimen.
The third dose was "well tolerated among 1,678 children under 5 years of age with a safety profile similar to placebo," Pfzier said as it announced the news.
Pfizer says its COVID-19 vaccine produces a strong immune response in kids under 5
Posted from npr.org
Medical
Health
Drugs
Pharmaceuticals
Posted 2 y ago
Responses: 2
2
2
0
1
1
0
This was what 1440 sent out in an e-mail today, they are a non partisan news source. ""Child Vaccine Data
A COVID-19 vaccine regimen developed by Pfizer and partner BioNTech demonstrated 80% efficacy against symptomatic infections in children aged 6 months to 4 years, the companies announced yesterday. Children under 5 years old represent the last major age group without access to a vaccine against the coronavirus in the US.
The data relied on a three-dose regimen, with each dose one-tenth the amount of those administered to adults. Previous data from Moderna, which used a two-dose regimen, showed around 50% efficacy in children aged 6 months to 2 years and 37% efficacy from 2 to 6 years old.
Following the news, federal health officials said they would convene an outside expert panel to review the data from June 14-15, the next step toward emergency use authorization for young children. The age group represents about 6% of the US population, or around 20 million children."
80% effective, compared to 37% for Moderna? No way I would risk giving my young child a vaccine with 37% effective results. Not sure how it even got approved because from what I understood they are supposed to be at least 65%, or that's what they said when they we in development.
I am not anti vax, have my first 3 Pfizer shots, waiting for the 4th to be approved by my doctor. But something is wrong if they let a vaccine out for young kids that's only 37% effective.
A COVID-19 vaccine regimen developed by Pfizer and partner BioNTech demonstrated 80% efficacy against symptomatic infections in children aged 6 months to 4 years, the companies announced yesterday. Children under 5 years old represent the last major age group without access to a vaccine against the coronavirus in the US.
The data relied on a three-dose regimen, with each dose one-tenth the amount of those administered to adults. Previous data from Moderna, which used a two-dose regimen, showed around 50% efficacy in children aged 6 months to 2 years and 37% efficacy from 2 to 6 years old.
Following the news, federal health officials said they would convene an outside expert panel to review the data from June 14-15, the next step toward emergency use authorization for young children. The age group represents about 6% of the US population, or around 20 million children."
80% effective, compared to 37% for Moderna? No way I would risk giving my young child a vaccine with 37% effective results. Not sure how it even got approved because from what I understood they are supposed to be at least 65%, or that's what they said when they we in development.
I am not anti vax, have my first 3 Pfizer shots, waiting for the 4th to be approved by my doctor. But something is wrong if they let a vaccine out for young kids that's only 37% effective.
(1)
(0)
Read This Next
Continue with Facebook 
Continue with Google